Recent Company News

• 11:12 PM ET Dec 21, 2025
  

  Simcere Pharmaceutical Group subsidiary signs exclusive licensing agreement with Ipsen Pharma (HK$12.94, -0.17)

• 02:49 AM ET Dec 19, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:11 AM ET Dec 19, 2025
  

  Ipsen Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo (€120.10, 0.00)

• 11:31 AM ET Dec 15, 2025
  

  Ipsen completes acquisition of ImCheck Therapeutics (€122.30, 0.00)

• 07:34 AM ET Dec 11, 2025
  

  Rhythm announces preliminary data from exploratory Phase 2 Trial showing Setmelanotide demonstrated positive efficacy signal in Prader-Willi Syndrome ($104.77, 0.00)

• 01:11 AM ET Dec 11, 2025
  

  European Patent Office intends to grant a new patent for IRLAB's mesdopetam. (SEK 1.98, 0.00)

• 04:02 PM ET Dec 10, 2025
  

  Rhythm Pharmaceuticals to announce preliminary data on 11-Dec from exploratory Phase 2 Trial evaluating setmelanotide in Prader-Willi syndrome ($104.77, 0.00)

• 01:07 AM ET Dec 05, 2025
  

  Ipsen confirms Beaufour's Beech Tree share transfer to Alasol Foundation (€122.40, 0.00)

• 01:01 AM ET Dec 01, 2025
  

  Ipsen mourns the passing of Henri Beaufour (26% holder), founding family board member (€124.30, 0.00)

• 07:53 PM ET Nov 26, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap